Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/CD22 CAR-T for R/R B-cell Malignancies
NCT06213636Phase 2Recruiting
- Sponsor
- Essen BioTech
- Start
- Jul 2024
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of CD19/CD22-CAR T cells in B cell acute lymphoblastic leukemia (B-ALL), B cell lymphoma, non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), sponsored by Essen BioTech. Started Jul 2024; status: recruiting.
02
Drugs
CD19/CD22-CAR T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphomanon-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06213636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06213636.